SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION ARTICLE M impact

FDA Issues Complete Response Letter for Summit Therapeutics’ Ivonescimab BLA

Summit Therapeutics said the FDA will not approve its ivonescimab application in its current form, citing insufficient evidence of effectiveness without a statistically significant overall survival benefit.

SMMT

Summit Therapeutics said the FDA will not approve its ivonescimab application in its current form, citing insufficient evidence of effectiveness without a statistically significant overall survival benefit.Key Highlights:Original SEC Filing: Summit Therapeutics Inc. [ SMMT ] - 8-K - Nov. 16, 2026Th…

Related stories